<DOC>
	<DOCNO>NCT00703872</DOCNO>
	<brief_summary>A Phase II , Open Label , Multi-Center , Proof-Of-Concept Study determing whether treatment HDV-Interferon ( HDV-IFN ) , oral subcutaneous ( injection ) rout , ribavirin result similar efficacy [ Rapid Virologic Response ( RVR ) ] safety report efficacy safety pegylated alpha-interferon-2a ribavirin ( historical control ) patient chronic hepatitis C ( treatment na誰ve oral route non-responders SC route respectively ) .</brief_summary>
	<brief_title>HDV-Interferon Treatment Chronic Hepatitis C Nonresponders Naive Hepatitis C Patients</brief_title>
	<detailed_description>Part 1 ( `` initial part '' ) - 4 week treatment ( 28 day ) : - All patient complete initial 4 week treatment HDV-Interferon ( HDV-IFN ) ( treatment na誰ve oral route non-responders SC route respectively ) ribavirin . - The Part 1 study shall assess whether 4-week treatment course HDV-Interferon ( HDV-IFN ) , orally subcutaneous injection , ribavirin result similar efficacy [ Rapid Virologic Response ( RVR ) ] safety report efficacy safety pegylated alpha-interferon-2a ribavirin ( historical control ) patient chronic hepatitis C ( treatment na誰ve non-responders ) . Part 2 ( `` continuation part '' ) - 44 20 week treatment + 24 week ( follow-up period ) : - Patients hepatitis C viral genotype 1 , achieve RVR , treat another 44 week therapy ( complete 48 week active treatment ) follow 24 week treatment-free follow-up period . - Patients hepatitis C viral genotype 3 , achieve RVR , treat another 20 week therapy ( complete 24 week active treatment ) follow 24 week treatment-free follow-up period . - Follow-up period ( 24 week ) : Thus , addition treatment Part 1 study , complete patient viral genotype 1 receive 44 week therapy 24 week treatment-free follow-up ; viral genotype 3 patient 20 week therapy &amp; 24 week treatment study drug free follow-up . - Overall study duration ( 72 48 week ) : Patients viral genotype 1 overall study duration 72 week ( 48 week therapy plus 24 week follow-up ) patient viral genotype 3 overall study duration 48 week ( 24 week therapy plus 24 week follow-up ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Inclusion Criteria Nonresponders : Patients &gt; 18 year establish chronic hepatitis C viral genotype 1 viral genotype 3 fail respond least 3month course pegylated interferon alpha 2a + ribavirin detectable HCV RNA baseline liver biopsy available within prior 12 month . Inclusion Criteria Naive : Treatment na誰ve patient &gt; 18 year , inclusive , eligible study . Patients viral genotype 1 viral genotype 3 , quantifiable HCVRNA &gt; 1000 IU/mL demonstrate PCR abnormal ALT ( within 6 month screen ) compensate liver disease without cirrhosis . Exclusion Criteria Nonresponders : Patients decompensated cirrhosis form liver disease Hb &lt; 10g/dL male &amp; Hb &lt; 9 g/dl female hepatocellular carcinoma active hepatitis B infection human immunodeficiency virus ( HIV ) preexist severe uncontrolled depression psychiatric disease significant cardiac disease renal disease seizure disorder retinopathy Exclusion Criteria Nonresponders : Patients decompensated cirrhosis form liver disease Hb &lt; 10g/dL male &amp; Hb &lt; 9 g/dl female hepatocellular carcinoma active hepatitis B infection HIV preexist severe uncontrolled depression psychiatric disease significant cardiac disease renal disease seizure disorder retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Naive</keyword>
	<keyword>Nonresponders</keyword>
	<keyword>Interferon</keyword>
	<keyword>Patients Chronic Hepatitis C</keyword>
</DOC>